Intended for healthcare professionals
Search
Toggle navigation
Current issue
Archive
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
Editorial board
For authors
Advertising
Contact us
News
Web Exclusives
Register
FREE
Sign in
×
Remember me
Not registered?
Forgot your password?
Methicillin-resistant Staphylococcus aureus
Sid Orpin
With the ever-increasing frequency of tabloid headlines describing the development of ‘super bugs’ that are resistant to modern antibiotics, it is easy to fall into the trap of regarding such events as a purely modern phenomenon. In fact, resistance to antimicrobial agents rapidly followed their initial introduction. The emergence of one such organism, methicillin-resistant Staphylococcus aureus (MRSA), has perhaps had more impact on medical care for patients and implications for the health workers dealing with them than any other. Healthcare facilities all over the world invest resources to try to reduce the threat it poses to those they care for, with varying levels of success. This article reviews the emergence of MRSA, its epidemiology, treatment and basic infection control measures.
Dermatology in practice
2003;
11
(1): 22–26
To continue reading this article, please
sign in
or
register
.
Follow us on
|
|
Latest News
LEO Pharma receives MHRA approval for Anzupgo cream in chronic hand eczema
Galderma shares positive phase 3 data for nemolizumab in prurigo nodularis
J&J/Protagonist’s icotrokinra shows promise in phase 3 plaque psoriasis trial
UCB’s Bimzelx approved by FDA to treat hidradenitis suppurativa
LEO Pharma announces long-term results for Adbry in atopic dermatitis
This site uses cookies in order to function properly and to allow us to improve our service. By using this site you consent to the use of cookies as set out in our
privacy policy